-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-01 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-01 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-01 in Non-Small Cell Lung Cancer Drug Details: TG-01...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-01 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-01 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-01 in Pancreatic Ductal Adenocarcinoma Drug Details: TG-01 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ONCOS-102 in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ONCOS-102 in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ONCOS-102 in Peritoneal Cancer Drug Details: ONCOS-102 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Acute Lymphocytic Leukemia (ALL,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-01 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-01 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-01 in Pancreatic Cancer Drug Details: TG-01 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ELU-001 in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ELU-001 in Peritoneal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ELU-001 in Peritoneal Cancer Drug Details: ELU-001 is under development for the...
-
Product Insights
NewMalignant Pleural Mesothelioma – Drugs In Development, 2024
Empower your strategies with our Malignant Pleural Mesothelioma – Drugs In Development, 2024 report and make more profitable business decisions. Malignant pleural mesothelioma is a rare cancer of the lining around the lungs, called the pleura. It is caused by asbestos fibers. After inhalation, the fibers can embed in the pleura, causing inflammation and scarring. Over time, these processes can lead to the development of mesothelioma tumors. The most common symptoms of pleural mesothelioma include difficulty breathing, swelling, back pain, and...
-
Product Insights
NewPlasma Cell Neoplasm – Drugs In Development, 2024
Empower your strategies with our Plasma Cell Neoplasm – Drugs In Development, 2024 report and make more profitable business decisions. Plasma Cell Neoplasm or plasma cell cancer is a group of diseases involving B-cells. These tumors are found in soft tissues that can be malignant or benign. Multiple Myeloma, lymphoplasmacytic lymphoma, plasmacytoma are the types of plasma cell cancers. Of all three multiple Myeloma is the most common and aggressive form. Age, chronic infection, exposure to radiation, hereditary factors, are some...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Colorectal Cancer Drug Details: RP-1 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BAY-3178275 in Diabetic Neuropathic Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BAY-3178275 in Diabetic Neuropathic Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BAY-3178275 in Diabetic Neuropathic PainDrug Details:BAY-3178275 is under development for the treatment...